NCT02824718View on ClinicalTrials.gov

Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 6, 2017

Primary Completion Date

May 28, 2020

Study Completion Date

May 28, 2020

Conditions

Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment

Interventions

DRUG

Teriparatide

human recombinant parathormone

DRUG

Thiazide

Diuretic

DRUG

Potassium sparing diuretic

Diuretic

DRUG

Alfacalcidol

Belongs to the class of vitamin D and analogues

Trial Locations (1)

75015

AP-HP Hopital Europeen Georges Pompidou, Paris

All Listed Sponsors

collaborator

Ministry of Health, France

OTHER_GOV

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02824718 - Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism | Biotech Hunter | Biotech Hunter